Skip to main content
. 2021 Apr 16;14(4):369. doi: 10.3390/ph14040369
AGP α1-acid glycoprotein
BPH Benign prostatic hyperplasia
BSA Bovine serum albumin
CAT Catalase
CD Cyclodextrin
COX2 Cyclooxygenase-2
CS Chitosan
CXCR4 Chemokine receptor Type 4
DNMT1 DNA-methyltransferase 1
DOX Doxorubicin
eEF-2K Eukaryotic elongation Factor 2 kinase
EMT Epithelial-mesenchymal transition
EZH2 Enhancer of zeste homolog 2
GK Gamma Knife
Grb2 Growth factor receptor-binding protein 2
GSH Glutathione
GSH-Px Glutathione peroxidase
GSK Glycogen synthase kinase
HDAC Histone deacetylase
HSA Human serum albumin
IC50 50% inhibitory concentration
IFN Interferon
IL Interleukin
I3M Indirubin-3-monoxime
JAK Janus kinase
JNK c-Jun N-terminal kinase pathway
LD50 Median lethal dose
LNPs Lipid-based nanoparticles
LPA Lysophosphatidic acid
MA Myristic acid
MAPK Mitogen-activated protein kinase
MDA malondialdehyde
MMP9 Matrix metallopeptidase 9
MOMP Mitochondrial outer membrane permeability
mTOR Mammalian target of rapamycin
NF-Kb Nuclear factor kappa B
NK Natural killer
NLCs Nanostructured lipid carriers
PBS Phosphate-buffered saline
PCL Poly-ε-caprolactone
PEG Polyethylene glycol
P-gp P-glycoprotein
PI3K Phosphoinositide 3-kinases
PLGA Poly-lactide-co-glycolide
PPARγ Peroxisome proliferator-activated receptor-γ
PTEN Phosphatase and tensin homolog
PTK Protein tyrosine kinase
PTX Paclitaxel
ROS Reactive oxygen species
SLNs Solid lipid nanocarriers
SOD Superoxide dismutase
STAT Signal transducer and activator of transcription
TF Transferrin
TGF-β1 Transforming growth factor-beta 1
TKI Tyrosine kinase inhibitors
TME Tumor microenvironment
TNBC Triple-negative breast cancer
TQ Thymoquinone
TRAIL TNF-related apoptosis-inducing ligand
TSG Tumor suppressor genes
VCAN Versican
VEGFR Vascular endothelial growth factor Receptor